References:

1) US Food and Drug Administration, (**2004**), Pharmaceutical CGMPs for the 21st Century—A Risk Based Approach, Final Report, U.S. Department of Health and Human Services.
2) The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, (**2006**), Quality Guideline Q8 Pharmaceutical Development.
3) The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, (**2006**), Quality Guideline Q9 Quality Risk Management.
4) Yu L. X., (**2008**), Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control, *Pharmaceutical Research*, **25**, 4, 781-791.
5) Hussain A. S., (**2003**), 'Quality by Design: Next Steps to Realize Opportunities?', presented at Office of Pharmaceutical Sciences, CDER, FDA.
6) US Food and Drug Administration, (**2004**), PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, *Guidance for Industry,* U.S. Department of Health and Human Services.
7) Cogdill R. P., Anderson C. A, Delgado-Lopez M., Molseed D., Chisholm R., Bolton R., Herkert T., Afnan A. M., DrennenIII J. K., (**2005**), Process Analytical Technology Case Study Part I: Feasibility Studies for Quantitative Near-Infrared Method Development, *AAPS PharmSciTech*, **6** (2), 262-272.
8) Bhatt D. A., Rane S. I., (**2011**), QbD approach to analytical rp-hplc method development and its validation, *International Journal of Pharmacy and Pharmaceutical Sciences*, **3**, 1, 179-187.
9) Sistare F., Berry L. St. P., Mojica C. A., (**2005**), Process Analytical Technology: An Investment in Process Knowledge, Organic Process Research & Development, **9**, 332-336.
10) Kirsch J.D., Drennen J.K., (**1995**), Determination of film-coated tablet parameters by near-infrared spectroscopy, *J Pharm Biomed Anal.*, **13**, 1273-1281.
11) Sekulic S.S., Wakeman J., Doherty P., Hailey P.A., (**1998**), Automated system for the on-line monitoring of powder blending processes using near-infrared spectroscopy. Part II. Qualitative approaches to blend evaluation, *J Pharm Biomed Anal*., **17**, 1285-1309.
12) Rantanen J., Jørgensen A., Rasanen E., (**2001**), Process analysis of fluidized bed granulation, AAPS PharmSciTech., **2,** 21-22.

13) Pohl, M., Schweitzer, M., Hansen, G.,Hanna, B.M., Borman, P., Smith, K., Larew, J., Nethercote, P., (**2010**), Implications and opportunities of applying the principles of QbD to analytical measurements, *Pharm. Technol. Eur.*, **22** (2), 29–36.

14) Schweitzer M., Pohl M., Hanna-Brown M., Nethercote P., Borman P., Hansen G., Smith K., Lare J., (**2010**), Implications and opportunities of applying QbD principles to analytical measurements, *Pham. Tech.*, **34,** 52–59.

15) Juran, J.M., (**1992**), Juran on Quality by Design – The New Steps for Planning Quality into Goods and Services, The Free Press.

16) Venkateshwaran, T.G., (**2009**), Global regulatory submissions for QbD: Wyeth's experience in the CMC pilot, *Pharm. Technol.*, **33** (10), 96–102.

17) McCurdy V., am Ende M.T., Bush F.R., Mustakis J., Rose P., Berry M., (**2010**), Quality by design using an integrated active pharmaceutical ingredient – drug product approach to development, Pharm. Eng., **30** (4), 12–32.

18) Rignall A., (**2011**), Applying Quality by Design Principles to Analytical Methods Associated with OINDPs, *IPAC-RS Conference,* "Bringing Value to the Patient in a Changing World", March.

19) Nasr M. M., CDER, FDA, (**2007**), "FDA's Pharmaceutical Quality Assessment Systems in the 21st Century – A Modern Risk-Based Approach", presented at the Pharmaceutical Technology Annual Conference, July 24.

20) McCurdy V., (2011), Quality By Design, in 'Process Understanding: For Scale-Up and Manufacture of Active Ingredients', First Edition. Ed by Ian Houson, Wiley-VCH Verlag GmbH & Co. KGaA.

21) Liam C Feely, (**2011**), Industry view and experience of QbD, presented at AAPS Chicagoland Pharmaceutical Discussion Group Symposium.

22) R.Gopinath, R.A.S. Naidu, (**2011**) Pharmaceutical Preformulation Studies – Current Review, *International Journal of Pharmaceutical & Biological Archives,* **2**(5), 1391-1400.

23) Fiese E.F., Hagen T.A., (**1986**), Preformulation (chap. 8), Theory and Practice of Industrial Pharmacy, Eds. Lachman L., Lieberman H.A., Kanig J.L., Philadelphia: Lea & Febiger, 171–96.

24) Carstensen J.T., (**2000**), Preformulation (chap. 9). Drug Stability, Eds. Carstensen J.T., Rhodes C.T., 3rd ed., New York: Marcel Dekker, 237–60.

25) DiFeo T. J., (**2003**), Drug Product Development: A Technical Review of Chemistry, Manufacturing, and Controls Information for the Support of Pharmaceutical Compound Licensing Activities, *Drug Development And Industrial Pharmacy*, **29**, 9, 939–958.

26) Chrzanowski F., (**2008**), Preformulation Considerations for Controlled Release Dosage Forms: Part I Selecting Candidates, *AAPS PharmSciTech*, **9**, 2, 635 – 638.

27) Chrzanowski F., (**2008**), Preformulation Considerations for Controlled Release Dosage Forms: Part I Selected Candidate Support, *AAPS PharmSciTech*, **9**, 2, 635 – 638.

28) Brittain H. G., (**2008**), Introduction and Overview to the Preformulation Development of Solid Dosage Forms (Cha. 1), In 'Preformulation in Solid Dosage Form Development', Drugs and Pharmaceutical Sciences, Vol. 178, Eds. Adyeye M. C., Brittain H. G., NewYork: Informa Healthcare, 1-16.

29) Torrealday N., Gonzalez L., Alonso R. M., Jimenez R. M., Ortiz-Lastra E., (**2003**), Experimental design approach for the optimization of a HPLC-fluorimetric method for the quantitation of the angiotensin II receptor antagonist telmisartan in urine, *J. Pharm. Biomed. Anal.*, **32,** 847–857.

30) Peter F.G., Bernard A.O., (**2008**), A quality by design approach to impurity method development for atomoxetine hydrochloride, *J. Pharm. Biomed. Anal.,* **46**, 431-441.

31) McBrien M., (**2010**), Practical implications of quality by design to chromatographic method development, *Chromatogr. Today*, **2**, 30–33.

32) Karmarkar S., Garber R., Genchanok Y., George S., Yang X., Hammond R., (**2011**), Quality by Design (QbD) Based Development of a Stability Indicating HPLC Method for Drug and Impurities, Journal of Chromatographic Science, **49**, 439 – 446.

33) K. Ishikawa, (**1985**), What is Total Quality Control? The Japanese Way, (Prentice-Hall, Englewood Cliffs, NJ, 63–64.